Table 1.
Characteristics of 87 patients receiving abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer.
| Demographics at the Time of Initial Prostate Cancer Diagnosis | |
|---|---|
| Median age (years) | 64 (43–89) |
| Median prostate-specific antigen (ng/dL) | 7 (0–3229) |
| Stage | |
| T1–T2b | 24 (28%) |
| T2c | 25 (29%) |
| T3+ | 38 (43%) |
| N+ | 23 (38%) |
| M+ | 18 (56%) |
| Gleason grade | |
| 5–6 | 11 (13%) |
| 7 | 27 (31%) |
| 8–10 | 49 (56%) |
| Radical prostatectomy | 51 (71%) |
| Patient Characteristics at the Time of Initiation of Abiraterone Acetate and Prednisone for Castration-Resistant Stage | |
| Median age (years) | 73 (54–90) |
| Median prostate-specific antigen (ng/dL) | 66 (0–100) |
| Median body mass index (kg/m2) | 30 (21–56) |
| Bone metastases | 73 (84%) |
| Soft tissue metastases | 43 (49%) |
| Previous androgen-deprivation therapy | 87 (100%) |
| Previous docetaxel | 56 (65%) |
| Previous enzalutamide | 5 (6%) |
| Previous cabazitaxel | 5 (6%) |
| Time from initial diagnosis (years) | 8 (1–24) |
| Patients alive at the time of data analysis | 38 (44%) |
Data are given as median (range) or count (percent of the entire cohort).